

Supporting Information

for

Synthesis of indolo[1,2-c]quinazolines from 2-alkynyylaniline derivatives through Pd-catalyzed indole formation/cyclization with *N,N*-dimethylformamide dimethyl acetal

Antonio Arcadi¹, Sandro Cacchi², Giancarlo Fabrizi², Francesca Ghirga³, Antonella Goggiamani², Antonia Iazzetti^{*2} and Fabio Marinelli^{*1}

Address: ¹Dipartimento di Scienze Fisiche e Chimiche, Università di L'Aquila, Via Vetoio, 671010 Coppito (AQ), Italy, ²Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza, Università di Roma, P.le A. Moro 5, 00185, Rome, Italy and ³Center for Life Nano Science@Sapienza, Istituto Italiano di Tecnologia, Viale Regina Elena 291, 00161 Rome, Italy

*Corresponding author

Email: Fabio Marinelli - fabio.marinelli@univaq.it

Experimental procedures, characterization data and copies of NMR spectra

Contents


General information:	S2
General procedure:	S3
Characterization data (5a–d ; 14a–e ; 9a):	S4
Characterization data (10a–p ; 13a–e):	S7
References	S15
Copies of NMR spectra:	S16

General information


Melting points are uncorrected. All of the reagents, catalysts, and solvents are commercially available and were used as purchased, without further purification. Starting materials were purified on axially compressed columns, packed with SiO₂ 25–40 μ m, connected to a preparative pump for solvent delivery and to a refractive index detector, and eluting with *n*-hexane/EtOAc mixtures. Reaction products were purified by flash chromatography using SiO₂ as stationary phase, eluting with *n*-hexane/ethyl acetate or MeOH/CHCl₃ mixtures. ¹H NMR (400.13 MHz), ¹³C NMR (100.6 MHz) and ¹⁹F NMR (376.5 MHz) spectra were recorded with a Bruker Avance 400 spectrometer. Splitting patterns are designed as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), or bs (broad singlet). IR spectra were recorded with a Jasco FT/IR-430 spectrometer. HRMS spectra were recorded with Orbitrap Exactive Mass spectrometer with ESI source.

The appropriate *o*-(*o*-aminophenylethynyl) trifluoroacetanilides **5** and *o*-(*o*-aminophenylethynyl)anilines **15** were prepared, usually in high yields, via a Sonogashira cross-coupling of 2-iodotrifluoroacetanilides or 2-iodoaniline with 2-ethynylanilines.¹

2-(*o*-Aminophenyl)indoles **14** were synthesized through two different procedures depending on the substitution of the indole derivatives: indoles **14a–c** (R¹ = R³, R² = H) were prepared via palladium-catalyzed cyclization of the corresponding *o*-(*o*-aminophenylethynyl)aniline **15a–c** (Scheme 1).² Indoles **14d,e** (R¹ ≠ R³) were obtained by cyclization of the corresponding *o*-(*o*-aminophenylethynyl) trifluoroacetanilides **5** with PdCl₂(MeCN)₂² followed by hydrolysis of -COCF₃ on the crude (Scheme 2).



Scheme S1: Preparation of **14a–c**.



Scheme S2: Preparation of **14d,e**.

Experimental procedures

Typical procedure for preparation of 12-(4-methoxyphenyl)indolo[1,2-*c*]quinazolines 10a–p. Preparation of 10a.

In a 50 mL Carousel Tube Reactor (Radely Discovery Technology) containing a magnetic stirring bar Pd(OAc)₂ (4.0 mg, 0.018 mmol) and dppp (7.4 mg, 0.018 mmol) were dissolved at room temperature with 1 mL of anhydrous MeOH. Then 2-((2-aminophenyl)ethynyl)trifluoroacetanilide (**5a**, 105.0 mg, 0.345 mmol), 4-methoxyphenylboronic acid (**12a**, 104.8 mg, 0.690 mmol), K₃PO₄ (146.4 mg, 0.690 mmol) and 1.0 mL of MeOH were added. The mixture was stirred at 60 °C under oxygen atmosphere until conversion of *o*-(*o*-aminophenylethynyl) trifluoroacetanilide (**5a**) into indole **11a** was completed (3 h). Then, in order to allow complete hydrolysis of **11a** to **9a**, the reaction mixture was warmed at 100 °C for 16 h, cooled to room temperature, diluted with ether and washed with a saturated solution of NaHCO₃. The organic extract was dried over Na₂SO₄ and concentrated under reduced pressure. The residue was dissolved in 2 mL of DMF and DMFDMA (230 µL, 1.725 mmol) was added. The mixture was stirred at 100 °C for 8 h, cooled to room temperature, diluted with ether, washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash chromatography (silica gel, *n*-hexane/EtOAc 85:15 v/v) to afford 12-(4-methoxyphenyl)indolo[1,2-*c*]quinazoline **10a** (85.0 mg, 76%).


Typical procedure for preparation of indolo[1,2-*c*]quinazolines 13a-d. Preparation of 13d.

To a solution of 2-(1*H*-indol-2-yl)-4-methylaniline (**14d**, 76.7 mg, 0.345 mmol) in 2 mL of DMF, DMFDMA (91 µL, 0.690 mmol) was added; the mixture was stirred at 100 °C. After 25 h, the reaction mixture was cooled to room temperature, diluted with ether and washed with a saturated solution of NaHCO₃. The organic layer was dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash chromatography (silica gel, *n*-hexane/EtOAc 85/15 v/v) to afford 2-methylindolo[1,2-*c*]quinazoline **13d** (76.1 mg, 95%).

Sequential preparation of indolo[1,2-*c*]quinazoline 13a from 15a


To a stirred solution of PdCl₂(MeCN)₂ (6.2 mg, 0.024 mmol) in 2 mL of DMF *o*-(*o*-aminophenylethynyl)aniline (**15a**, 100 mg, 0.481 mmol) and DMFDMA (128 µL, 0.962 mmol) were added; the mixture was stirred at 100 °C under N₂ atmosphere for 24 h. Then the reaction mixture was cooled to room temperature, diluted with ether and washed with a saturated solution of NaHCO₃. The organic layer was dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash chromatography (silica gel, *n*-hexane/EtOAc 80/20v/v) to afford indolo[1,2-*c*]quinazoline **13a** (74.8 mg, 71%).

Characterization data (5a–d; 14a–e; 9a)




***N*-(2-((2-Aminophenyl)ethynyl)phenyl)-2,2,2-trifluoroacetamide (5a)**³

Pale yellow powder, **yield**: 82%; mp: 100-102 °C; ¹H NMR (CDCl₃): δ 8.87 (bs, 1H), 8.39 (d, *J* = 7.6 Hz, 1H), 7.58 (d, *J* = 7.6 Hz, 1H), 7.46-7.43 (m, 2H), 7.36-7.23 (m, 2H), 6.77 (d, *J* = 4.0 Hz, 2H), 4.29 (bs, 2H); ¹³C NMR (CDCl₃): δ 154.5 (q, *J*_{CF} = 37 Hz), 147.9, 135.8, 132.2, 131.7, 130.8, 129.8, 126.2, 120.9, 119.8, 116.0 (q, *J*_{CF} = 241 Hz), 114.3, 113.7, 106.3, 94.7, 88.1; ¹⁹F NMR (CDCl₃): δ -75.7.




***N*-(2-((2-Aminophenyl)ethynyl)-4-methylphenyl)-2,2,2-trifluoroacetamide (5b)**^{1b}

White powder, **yield**: 67%; mp: 141-143 °C; ¹H NMR (DMSO-*d*₆): δ 11.17 (bs, 1H), 7.57 (s, 1H), 7.35 (d, *J* = 8.4 Hz, 1H), 7.27 (d, *J* = 8.0 Hz, 1H), 7.18 (d, *J* = 7.2 Hz, 1H), 7.09 (t, *J* = 7.2 Hz, 1H), 6.73 (d, *J* = 8.4 Hz, 1H), 6.55 (t, *J* = 7.2 Hz, 1H), 5.56 (bs, 2H), 2.35 (s, 3H); ¹³C NMR (DMSO-*d*₆): δ 155.7 (q, *J*_{CF} = 36 Hz), 150.2, 137.6, 133.1, 132.9, 132.2, 130.6, 130.0, 126.9, 120.5, 116.6 (q, *J*_{CF} = 287 Hz), 116.2, 114.4, 105.5, 92.3, 90.5, 20.8. ¹⁹F NMR (DMSO-*d*₆): δ: -75.6.




Methyl 4-amino-3-((5-methyl-2-(2,2,2-trifluoroacetamido)phenyl)ethynyl)benzoate (5c)

Pale yellow powder, **yield**: 37%; mp: 161-163 °C; ¹H NMR (CDCl₃): δ 8.71 (bs, 1H), 8.20 (d, *J* = 8.4 Hz, 1H), 8.07 (d, *J* = 2.0 Hz, 1H), 7.88 (dd, *J*₁ = 8.8 Hz, *J*₂ = 1.8 Hz, 1H), 7.39 (s, 1H), 7.25 (d, *J* = 8.4 Hz, 1H), 6.75 (d, *J* = 8.4 Hz, 1H), 4.72 (bs, 2H), 3.90 (s, 3H), 2.38 (s, 3H); ¹³C NMR (CDCl₃): δ 166.3, 154.5 (q, *J*_{CF} = 37 Hz), 151.4, 135.7, 134.6, 133.4, 132.3, 132.2, 130.8, 120.1, 119.8, 115.8 (q, *J*_{CF} = 287 Hz), 113.7, 113.5, 105.6, 92.8, 88.8, 51.9, 20.8.




N-(2-((2-Amino-5-methylphenyl)ethynyl)phenyl)-2,2,2-trifluoroacetamide (5d) ^{1b}

White powder, **yield:** 70%; mp :137-139 °C; ¹H NMR (CDCl₃): δ 8.88 (bs, 1 H), 8.39 (d, *J* = 8,4 Hz, 1H), 7.57 (dd, *J*₁ = 7.6 Hz, *J*₂ = 1.2 Hz, 1H), 7.50-7.38 (m, 1H), 7.32-7.22 (m, 1H), 7.18 (s, 1H), 7.05 (dd, *J*₁ = 8.0 Hz, *J*₂ = 1.6 Hz, 1H), 6.70 (d, *J* = 8.0 Hz, 1H), 4.15 (bs, 2H), 2.28 (s, 3H); ¹³C NMR (CDCl₃): δ 154.5 (q, *J* = 37.5 Hz), 145.6, 135.7, 132.2, 131.8, 131.7, 129.7, 127.6, 125.6, 119.8, 115.7 (q, *J* = 287 Hz), 115.0, 113.8, 106.3, 95.0, 87.8, 20.3. ¹⁹F NMR (CDCl₃): δ -75.7.




2-(1H-Indol-2-yl)aniline (14a) ⁴

Pale yellow powder, **yield:** 82%; lit ⁴ mp: 163-165 °C; mp: 166-168 °C; ¹H NMR (CDCl₃): δ 8.47 (bs, 1H), 7.67 (d, *J* = 7.2 Hz, 1H), 7.44-7.40 (m, 2H), 7.25-7.15 (m, 3H), 6.91-6.83 (m, 2H), 6.75 (s, 1H), 4.12 (bs, 2H); ¹³C NMR (CDCl₃): δ 144.0, 136.1, 135.9, 129.2, 129.1, 128.9, 122.1, 120.4, 120.2, 119.1, 118.8, 116.6, 110.8, 101.6.



4-Methyl-2-(5-methyl-1H-indol-2-yl)aniline (14b) ⁵


Beige powder, **yield:** 63%; lit ⁵ mp: 195-197 °C; mp: 194-196 °C; ¹H NMR (CDCl₃): δ 8.33 (bs, 1H), 7.34 (s, 1H), 7.20 (t, *J* = 7.8 Hz, 1H), 7.13 (d, *J* = 1.6 Hz, 1H), 6.95 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.2 Hz, 1H), 6.91 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.6 Hz, 1H), 6.65 (d, *J* = 8.0 Hz, 1H), 6.55 (s, 1H), 3.84 (bs, 2H), 2.38 (s, 3H), 1.22 (s, 3H); ¹³C NMR (CDCl₃): δ 141.3, 136.2, 134.5, 129.54, 129.49, 129.3, 129.2, 128.5, 123.7, 120.0, 119.1, 116.9, 110.4, 101.0, 21.5, 20.5.



Methyl 2-(2-amino-5-(methoxycarbonyl)phenyl)-1H-indole-5-carboxylate (14c)

Pale yellow powder, **yield:** 82%; mp: 198-200 °C; ¹H NMR (CDCl₃): δ 8.71 (bs, 1H), 8.42 (s, 1H), 8.08 (d, *J* = 1.6 Hz, 1H), 7.95 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.6 Hz, 1H), 7.87 (dd, *J*₁ = 8.4


Hz, $J_2 = 2.0$ Hz, 1H), 7.45 (d, $J = 8.4$ Hz, 1H), 6.85-6.80 (m, 2H), 4.62 (bs, 2H), 3.96 (s, 3H), 3.90 (s, 3H); ^{13}C NMR (CDCl_3): δ 168.1, 166.9, 148.5, 138.8, 135.9, 131.16, 131.11, 128.4, 123.9, 123.4, 122.4, 120.1, 116.9, 115.3, 110.6, 102.9, 51.9, 51.8.



2-(1H-Indol-2-yl)-4-methylaniline (14d) ⁵


Off-white powder, **yield**: 72%; lit ⁵ mp: 162-163 °C; mp: 165-167 °C; ^1H NMR ($\text{DMSO } d_6$): δ 11.2 (s, 1H), 7.52 (d, $J = 7.6$ Hz, 1H), 7.38 (d, $J = 8.0$ Hz, 1H), 7.20 (s, 1H), 7.05 (t, $J = 7.4$ Hz, 1H), 7.00 (t, $J = 7.4$ Hz, 1H), 6.89 (d, $J = 8.0$ Hz, 1H), 6.74 (d, $J = 8.4$ Hz, 1H), 6.66 (s, 1H), 4.98 (s, 2H), 2.23 (s, 3H); ^{13}C NMR ($\text{DMSO } d_6$): δ 143.6, 136.69, 136.68, 129.4, 129.1, 125.4, 121.4, 120.1, 119.4, 117.5, 116.5, 111.5, 100.4, 20.6.

2-(5,7-Dimethyl-1H-indol-2-yl)aniline (14e)




Beige powder, **yield**: 80%; mp: 192-194 °C; ^1H NMR (CDCl_3): δ 8.27 (bs, 1H), 7.43 (dd, $J_1 = 7.6$ Hz, $J_2 = 1.6$ Hz, 1H), 7.32 (s, 1H), 7.21 (td, $J_1 = 7.7$ Hz, $J_2 = 1.2$ Hz, 1H), 6.92-6.88 (m, 2H), 6.84 (d, $J = 8.0$ Hz, 1H), 6.67 (s, 1H), 4.13 (bs, 2H), 2.52 (s, 3H), 2.47 (s, 3H); ^{13}C NMR (CDCl_3): δ 144.1, 135.6, 134.1, 129.7, 129.2, 128.9, 128.7, 124.5, 119.7, 119.1, 118.9, 117.7, 116.4, 101.7, 21.4, 16.7.

2-(3-(4-Methoxyphenyl)-1H-indol-2-yl)aniline (9a)




Brown oil, **yield**: 70%; mp: 155-157 °C; ^1H NMR (CDCl_3): δ 8.29 (bs, 1H), 7.84 (d, $J = 8.0$ Hz, 1H), 7.41 (d, $J = 8.8$ Hz, 3H), 7.42-7.26 (m, 2H), 7.23-7.19 (m, 2H), 6.92 (d, $J = 8.8$ Hz, 2H), 6.82 (t, $J = 7.2$ Hz, 1H), 6.71 (d, $J = 8.0$ Hz, 1H), 3.84 (s, 3H), 3.75 (bs, 2H); ^{13}C NMR (CDCl_3): δ 158.0, 144.6, 136.0, 131.7, 131.3, 129.9, 129.6, 127.7, 127.3, 122.5, 120.3, 119.5, 118.6, 118.4, 116.1, 114.9, 114.1, 111.0, 55.2.

Characterization data (10a–p; 13a–e)




12-(4-Methoxyphenyl)indolo[1,2-c]quinazoline (10a)

Pale yellow powder, **yield**: 76%, mp: 135-136 °C; **IR (KBr)**: 2930, 2858, 2828, 1614, 1556, 1455 cm^{-1} ; **^1H NMR (CDCl_3)**: δ 9.16 (s, 1H), 8.02 (d, J = 7.9 Hz, 1H), 7.82 (t, J = 7.0 Hz, 2H), 7.63 (d, J = 7.7 Hz, 1H), 7.65-7.41 (m, 5H), 7.28-7.22 (m, 1H), 7.13 (d, J_1 = 7.9 Hz, 2H), 3.96 (s, 3H); **^{13}C NMR (CDCl_3)**: δ 159.2, 139.4, 137.5, 131.7, 130.8, 129.4, 128.9, 127.7, 127.31, 127.29, 126.0, 124.3, 123.7, 123.0, 121.8, 119.8, 114.5, 112.6, 109.7, 55.4; **HRMS $[\text{M}+\text{H}]^+$** : calcd for $\text{C}_{22}\text{H}_{17}\text{N}_2\text{O}$ 325.1335, found 325.1335.




12-(p-Tolyl)indolo[1,2-c]quinazoline (10b)

Off-white powder, **yield**: 61%, mp: 192-193 °C; **IR (KBr)**: 3060, 2931, 2847, 1740, 1560, 1450 (cm^{-1}); **^1H NMR (CDCl_3)**: δ 8.92 (s, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.53-7.49 (m, 1H), 7.40-7.26 (m, 7H), 7.15-7.09 (m, 1H), 2.40 (s, 3H); **^{13}C NMR (CDCl_3)**: 140.1, 137.4, 137.3, 131.2, 130.54, 130.50, 129.8, 129.4, 128.8, 128.1, 127.4, 127.1, 124.0, 123.7, 122.8, 121.9, 119.8, 112.5, 109.5, 21.4; **HRMS $[\text{M}+\text{H}]^+$** : calcd for $\text{C}_{22}\text{H}_{17}\text{N}_2$ 309.1386, found 309.1385.




12-Phenylindolo[1,2-c]quinazoline (10c)

Yellow powder, **yield**: 75%, mp: 155-156 °C; **IR (KBr)**: 3066, 2934, 2853, 1740, 1579, 1450 (cm^{-1}); **^1H NMR (CDCl_3)**: δ 8.90 (s, 1H), 7.83 (d, J = 7.6 Hz, 1H), 7.67 (t, J = 8.4 Hz, 2H), 7.54-7.26 (m, 9H), 7.10 (d, J_1 = 7.6 Hz, J_2 = 0.8 Hz, 1H); **^{13}C NMR (CDCl_3)**: 140.2, 137.2, 134.3, 130.7, 130.4, 129.4, 129.0, 128.9, 128.2, 127.7, 127.5, 127.2, 124.2, 123.7, 122.9, 121.8, 119.7, 112.5, 109.5; **HRMS $[\text{M}+\text{H}]^+$** : calcd for $\text{C}_{21}\text{H}_{15}\text{N}_2$ 295.1230, found 295.1229.




12-(Naphthalen-1-yl)indolo[1,2-c]quinazoline (10d)

Pale yellow powder, **yield**: 60%, mp: 192-193 °C; **IR (KBr)**: 3042, 2925, 1618, 1469, 1445 (cm⁻¹); **¹H NMR (CDCl₃)**: δ 9.07 (s, 1H), 8.00-7.90 (m, 3H), 7.70 (d, *J* = 7.7 Hz, 1H), 7.59 (s, 1H), 7.58 (d, *J* = 1.3 Hz, 1H), 7.52 (d, *J* = 8.3 Hz, 1H), 7.46-7.36 (m, 2H), 7.34-7.25 (m, 3H), 7.24-7.18 (m, 1H), 7.13 (dd, *J*₁ = 8.0 Hz, *J*₂ = 0.9 Hz, 1H), 6.98-6.90 (m, 1H); **¹³C NMR (CDCl₃)**: δ 140.2, 137.3, 134.1, 132.7, 131.8, 131.1, 129.6, 129.0, 128.8, 128.7, 128.5, 128.4, 128.0, 127.3, 126.4, 126.20, 126.19, 126.0, 124.2, 122.9, 121.7, 120.2, 109.9, 109.6; **HRMS [M+H]⁺**: calcd for C₂₅H₁₇N₂ 345.1386, found 345.1385.



12-(4-(Trifluoromethyl)phenyl)indolo[1,2-c]quinazoline (10e)


Yellow powder, **yield**: 69%, mp: 188-189 °C; **IR (KBr)**: 2924, 2855, 1616, 1473 (cm⁻¹); **¹H NMR (CDCl₃)**: δ 9.00 (s, 1H), 7.93 (d, *J* = 7.8 Hz, 1H), 7.80-7.63 (m, 6H), 7.54-7.50 (m, 1H), 7.47-7.33 (m, 3H), 7.22-7.15 (m, 1H); **¹³C NMR (CDCl₃)**: δ 140.3 (q, *J*_{C-F} = 1.5 Hz, 1H), 138.5, 137.0, 131.0, 129.9, 129.8 (q, *J*_{CF} = 32 Hz, 1H), 129.6, 129.3, 128.5, 127.9, 127.4, 126.0 (q, *J*_{CF} = 4 Hz), 124.3 (q, *J*_{CF} = 272 Hz), 124.5, 123.5, 123.2, 121.3, 119.3, 110.8, 109.7; **¹⁹F NMR (CDCl₃)**: δ -63.33. **HRMS [M+H]⁺**: calcd for C₂₂H₁₄F₃N₂ 363.1104, found 363.1101.



12-(4-Bromophenyl)indolo[1,2-c]quinazoline (10f)


beige powder, **yield**: 60%, mp: 207-208 °C; **IR (KBr)**: 3042, 2921, 1629, 1457 cm⁻¹; **¹H NMR (CDCl₃)**: δ 8.96 (s, 1H), 7.89 (d, *J* = 7.4 Hz, 1H), 7.66-7.62 (m, 2H), 7.61 (d, *J* = 8.4 Hz, 2H), 7.55-7.46 (m, 1H), 7.44-7.30 (m 5H), 7.21-7.14 (m, 1H); **¹³C NMR (CDCl₃)**: δ 140.2, 137.1, 133.4, 132.4, 132.3, 130.1, 129.5, 129.1, 128.3, 127.7, 127.3, 124.3, 123.6,

123.0, 121.8, 121.5, 119.4, 111.0, 109.7; **HRMS** $[M+H]^+$: calcd for $C_{21}H_{14}BrN_2$ 373.0345, found 373.0334.




Methyl 4-(indolo[1,2-c]quinazolin-12-yl)benzoate (10g)

Pale yellow powder, **yield**: 59%, mp: 170-171 °C; **IR (KBr)**: 3404, 3048, 2923, 1637, 1475 (cm^{-1}); **1H NMR ($CDCl_3$)**: δ 9.03 (s, 1H), 8.26 (d, J = 8.4 Hz, 2H), 8.02-7.99 (m, 1H), 7.80 (td, J_1 = 8.3 Hz, J_2 = 1.1 Hz, 2H), 7.72 (d, J = 8.4 Hz, 2H), 7.65-7.61 (m, 1H), 7.54-7.42 (m, 3H), 7.28-7.22 (m, 1H), 4.00 (s, 3H); **^{13}C NMR ($CDCl_3$)**: δ 167.02, 140.3, 139.6, 137.1, 130.7, 130.3, 129.9, 129.6, 129.4, 129.3, 128.4, 127.9, 127.3, 124.4, 123.6, 123.1, 121.4, 119.4, 111.4, 109.7, 52.3; **HRMS** $[M+H]^+$: calcd for $C_{23}H_{17}N_2O_2$ 353.1285, found 353.1276.



12-(4-Chlorophenyl)indolo[1,2-c]quinazoline (10h)


Off-white powder, **yield**: 52%, mp: 236-237 °C; **IR (KBr)**: 3048, 2921, 1619, 1474 (cm^{-1}); **1H NMR ($CDCl_3$)**: δ 9.03 (s, 1H), 7.97 (d, J = 7.2 Hz, 1H), 7.77 (t, J = 8.2 Hz, 2H), 7.60-7.40 (m, 8H), 7.26-7.22 (m, 1H); **^{13}C NMR ($CDCl_3$)**: δ 140.2, 137.1, 133.6, 132.9, 132.0, 130.1, 129.4, 129.3, 129.1, 128.3, 127.7, 127.3, 124.3, 123.5, 123.0, 121.5, 119.4, 111.1, 109.7; **HRMS** $[M+H]^+$: calcd for $C_{21}H_{14}ClN_2$ 329.0840, found 329.0839.



12-(4-Fluoro-3-methylphenyl)indolo[1,2-c]quinazoline (10i)


Pale yellow powder, **yield**: 65%, mp: 165-166 °C; **IR (KBr)**: 3034, 2943, 1625, 1445 (cm^{-1}); **1H NMR ($CDCl_3$)**: δ 9.02 (s, 1H), 7.95 (d, J = 7.4 Hz, 1H), 7.75 (t, J = 8.4 Hz, 2H), 7.59-7.54 (m, 1H), 7.48-7.30 (m, 5H), 7.27-7.14 (m, 2H), 2.37 (s, 3H); **^{13}C NMR ($CDCl_3$)**: δ 161.0 (d, J_{CF} = 244 Hz), 140.2, 137.2, 133.6 (d, J_{CF} = 5 Hz), 130.4, 129.9 (d, J_{CF} = 4 Hz),

129.6, 129.4, 128.9, 128.2, 127.6, 127.2, 125.6 (d, $J_{CF} = 17$ Hz), 124.1, 123.6, 122.9, 121.8, 119.6, 115.7 (d, $J_{CF} = 23$ Hz), 111.6, 109.7, 14.7; **^{19}F NMR (CDCl_3)**: δ -118.7; **HRMS $[\text{M}+\text{H}]^+$** : calcd for $\text{C}_{22}\text{H}_{16}\text{FN}_2$, 327.1292, found 327.1297.




12-(o-Tolyl)indolo[1,2-c]quinazoline (10j)

Beige powder, **yield**: 56%, mp: 195-196 °C; **IR (KBr)**: 3055, 3014, 1617, 1604, 1469, 1449 (cm^{-1}); **^1H NMR (CDCl_3)**: δ 9.00 (s, 1H), 7.93 (d, $J = 8.0$ Hz, 1H), 7.70 (d, $J = 8.0$ Hz, 1H), 7.41-7.25 (m, 9H), 7.16-7.10 (m, 1H), 2.02 (s, 3H); **^{13}C NMR (CDCl_3)**: δ 140.0, 138.3, 137.3, 135.4, 133.5, 131.3, 130.5, 130.2, 129.1, 128.8, 128.2, 128.0, 127.5, 126.4, 124.1, 123.5, 122.8, 122.1, 119.9, 111.4, 109.6, 20.0; **HRMS $[\text{M}+\text{H}]^+$** : calcd for $\text{C}_{22}\text{H}_{17}\text{N}_2$ 309.1386, found 309.1384.



12-(4-Methoxyphenyl)-10-methylindolo[1,2-c]quinazoline (10k)


Pale yellow powder, **yield**: 63%, mp: 177-178 °C; **IR (KBr)**: 2930, 2858, 2828, 1614, 1556, 1455 (cm^{-1}); **^1H NMR (CDCl_3)**: δ 9.01 (s, 1H), 8.86 (d, $J = 8.4$ Hz, 1H), 7.84-7.75 (m, 2H), 7.52 (d, $J = 8.6$ Hz, 2H), 7.49-7.41 (m, 1H), 7.39 (s, 1H), 7.30-7.20 (m, 2H), 7.14 (d, $J = 8.6$ Hz, 2H), 3.96 (s, 3H), 2.51 (s, 3H); **^{13}C NMR (CDCl_3)**: δ 159.2, 140.1, 137.3, 133.9, 131.8, 130.9, 128.7, 128.0, 127.7, 127.6, 127.1, 126.5, 124.4, 123.6, 122.0, 119.3, 114.5, 111.8, 109.2, 55.4, 21.7; **HRMS $[\text{M}+\text{H}]^+$** : calcd for $\text{C}_{23}\text{H}_{19}\text{N}_2\text{O}$ 339.1492, found 339.1493.



10-Methyl-12-phenylindolo[1,2-c]quinazoline (10l)


Off-white powder, **yield**: 72%, mp: 173-174 °C; **IR (KBr)**: 3056, 2921, 2853, 1740, 1599, 1450 (cm^{-1}); **^1H NMR (CDCl_3)**: δ 8.94 (s, 1H), 7.79 (d, $J = 8.4$ Hz, 1H), 7.68 (d, $J = 8.2$ Hz, 2H), 7.55-7.46 (m, 4H), 7.45-7.34 (m, 2H), 7.30 (s, 1H), 7.21-7.09 (m, 2H), 2.41 (s, 3H); **^{13}C NMR (CDCl_3)**: δ 140.2, 137.3, 134.5, 134.0, 130.71, 130.68, 129.0, 128.8, 128.1,

127.8, 127.7, 127.6, 127.1, 124.5, 123.7, 121.9, 119.2, 112.1, 109.2, 21.7; **HRMS** $[M+H]^+$: calcd for $C_{22}H_{17}N_2$ 309.1386, found 309.1392.




12-(4-Fluoro-3-methylphenyl)-10-methylindolo[1,2-c]quinazoline (10m)

Pale yellow powder, **yield**: 76%, mp: 170-171 °C; **IR (KBr)**: 3058, 2922, 1639, 1445 (cm^{-1}); **1H NMR ($CDCl_3$)**: δ 9.01 (s, 1H), 7.87 (d, $J = 8.4$ Hz, 1H), 7.79 (d, $J = 8.0$ Hz, 1H), 7.75 (d, $J = 8.0$ Hz, 1H), 7.47 (t, $J = 7.6$ Hz, 1H), 7.44-7.33 (m, 3H), 7.32-7.18 (m, 3H), 2.52 (s, 3H), 2.42 (s, 3H); **^{13}C NMR ($CDCl_3$)**: δ 161.0 (d, $J_{CF} = 245$ Hz), 140.1, 137.3, 134.0, 133.6 (d, $J_{CF} = 5$ Hz), 130.7, 130.0 (d, $J_{CF} = 4$ Hz), 129.64, 129.56, 128.8, 128.2, 127.7, 121.1, 125.6 (d, $J_{CF} = 17$ Hz), 124.5, 123.5, 121.8, 119.1, 115.7 (d, $J_{CF} = 23$ Hz), 111.2, 109.3, 21.8, 14.8 (d, $J_{CF} = 3$ Hz); **^{19}F NMR ($CDCl_3$)**: δ -118.7; **HRMS** $[M+H]^+$: calcd for $C_{23}H_{18}FN_2$ 341.1449, found 341.1448.




Methyl 12-(4-methoxyphenyl)-10-methylindolo[1,2-c]quinazoline-2-carboxylate (10n)

Beige powder, **yield**: 60%, mp: 187.0-188 °C; **IR (KBr)**: 3400, 2935, 1634, 1450 (cm^{-1}); **1H NMR ($CDCl_3$)**: δ 9.04 (s, 1H), 8.55 (d, $J = 1.7$ Hz, 1H), 8.07 (dd, $J_1 = 8.4$, $J_2 = 1.7$ Hz, 1H), 7.88 (d, $J = 8.4$ Hz, 1H), 7.78 (d, $J = 8.4$ Hz, 2H), 7.54 (dd, $J_1 = 8.7$, $J_2 = 1.9$ Hz, 2H), 7.44 (s, 1H), 7.31 (dd, $J_1 = 8.4$, $J_2 = 0.9$ Hz, 1H), 7.17 (d, $J = 8.7$ Hz, 1H), 3.97 (s, 3H), 3.85 (s, 3H), 2.52 (s, 3H); **^{13}C NMR ($CDCl_3$)**: δ 166.3, 159.4, 143.3, 138.9, 134.3, 131.5, 130.8, 129.2, 128.2, 128.0, 127.8, 126.9, 125.7, 125.4, 124.9, 121.8, 119.5, 114.6, 113.0, 109.3, 55.4, 52.1, 21.7; **HRMS** $[M+H]^+$: calcd for $C_{25}H_{21}N_2O_3$ 397.1547, found 397.1556.




12-(4-Bromophenyl)-2-methylindolo[1,2-c]quinazoline (10o)

Light brown powder, **yield**: 58%, mp: 221-222 °C; **IR (KBr)**: 3056, 2922, 1620, 1559, 1469, 1221 (cm⁻¹); **¹H NMR (CDCl₃)**: δ 8.95 (s, 1H), 7.91 (d, *J* = 7.3 Hz, 1H), 7.64-7.58 (m, 3H), 7.58-7.49 (m, 2H), 7.46-7.32 (m, 4H), 7.24 (dd, *J*₁ = 8.0 Hz, *J*₂ = 1.6 Hz, 1H), 2.23 (s, 3H); **¹³C NMR (CDCl₃)**: 138.1, 137.4, 136.5, 133.5, 132.3, 132.1, 130.4, 130.0, 129.5, 128.2, 127.7, 124.2, 123.6, 123.0, 121.7, 121.3, 119.4, 110.8, 109.7, 21.7; **HRMS [M+H]⁺**: calcd for C₂₂H₁₆BrN₂ 387.0491, found 387.0492.




12-(2,6-Dimethoxyphenyl)indolo[1,2-c]quinazoline (10p)

Off-white powder, **yield**: 12%, mp: 210-211 °C; **IR (KBr)**: 3022, 2925, 1618, 1470 (cm⁻¹); **¹H NMR (CDCl₃)**: δ 9.07 (s, 1H), 7.98 (d, *J* = 7.3 Hz, 1H), 7.76 (d, *J* = 8.1 Hz, 1H), 7.59 (dd, *J*₁ = 8.1 Hz, *J*₂ = 0.9 Hz, 1H), 7.50-7.34 (m, 5H), 7.26-7.21 (m, 1H), 6.78 (d, *J* = 8.4 Hz, 2H), 3.66 (s, 6H); **¹³C NMR (CDCl₃)**: δ 159.1, 140.0, 137.4, 130.2, 129.71, 129.70, 128.67, 128.4, 127.5, 127.0, 123.9, 123.7, 122.7, 122.2, 120.5, 111.1, 109.6, 104.3, 103.7, 55.9; **HRMS [M+H]⁺**: calcd for C₂₃H₁₉N₂O₂ 355.1441, found 355.1436.




Indolo[1,2-c]quinazoline (13a)

White powder, **yield**: 86%, mp: 205-206 °C; **IR (KBr)**: 2922, 1593, 1458 (cm⁻¹); **¹H NMR (CDCl₃)**: δ 9.0 (s, 1H), 8.05 (d, *J* = 7.8 Hz, 1H), 7.95 (d, *J* = 7.8 Hz, 1H), 7.86-7.78 (m, 2H), 7.60-7.38 (m, 4H), 7.12 (s, 1H); **¹³C NMR (CDCl₃)**: δ 139.4, 137.0, 132.9, 130.3, 129.7, 129.1, 128.1, 127.7, 124.1, 123.1, 122.2, 121.3, 120.9, 109.9, 94.7 **HRMS [M+H]⁺**: calcd for C₁₅H₁₁N₂ 219.0917, found 219.0918.




2,10-Dimethylindolo[1,2-c]quinazoline (13b)

Light brown powder, **yield**: 87%, mp: 202.0-203.3 °C; **IR (KBr)**: 2922, 1540, 1370 (cm⁻¹); **¹H NMR (CDCl₃)**: δ 8.86 (s, 1H), 7.77-7.71 (m, 2H), 7.61 (d, *J* = 8.2 Hz, 1H), 7.51 (s, 1H), 7.27 (dd, *J*₁ = 8.2 Hz, *J*₂ = 1.5 Hz, 1H), 7.14 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.1 Hz, 1H), 6.93 (s, 1H), 2.47 (s, 3H), 2.45 (s, 3H); **¹³C NMR (CDCl₃)**: δ 137.6, 137.4, 136.5, 133.7, 133.1, 130.3, 130.0, 128.7, 127.9, 123.7, 123.0, 121.1, 120.5, 109.5, 93.9, 21.8, 21.6; **HRMS [M+H]⁺**: calcd for C₁₇H₁₅N₂ 247.1230, found 247.1230.




Dimethyl indolo[1,2-c]quinazoline-2,10-dicarboxylate (13c)

Yellow powder, **yield**: 81%, mp: 207-208 °C; **IR (KBr)**: 2916, 1701, 1386 (cm⁻¹); **¹H NMR (CDCl₃)**: δ 9.01 (s, 1H), 8.69 (d, *J* = 1.8 Hz, 1H), 8.53 (d, *J* = 1.0 Hz, 1H), 8.14 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.8 Hz, 1H), 8.08 (dd, *J*₁ = 8.7 Hz, *J*₂ = 1.5 Hz, 1H), 7.93 (d, *J* = 8.7 Hz, 1H), 7.78 (d, *J* = 8.5 Hz, 1H), 7.26 (s, 1H), 3.95 (s, 3H), 3.93 (s, 3H); **¹³C NMR (CDCl₃)**: δ 167.3, 166.3, 142.6, 138.4, 133.5, 132.6, 130.2, 129.3, 129.28, 128.5, 126.4, 125.3, 123.9, 123.8, 121.0, 109.8, 96.7, 52.5, 52.2; **HRMS [M+H]⁺**: calcd for C₁₉H₁₅N₂O₄ 335.1026, found 335.1022.



2-Methylindolo[1,2-c]quinazoline (13d)

Off-white powder, **yield**: 95%, mp: 145-146 °C; **IR (KBr)**: 2916, 2857, 1617, 1488, 1376 (cm⁻¹); **¹H NMR (CDCl₃)**: δ 8.89 (s, 1H), 7.86 (d, *J* = 8.0 Hz, 1H), 7.78-7.72 (m, 2H), 7.61 (d, *J* = 8.0 Hz, 1H), 7.39-7.26 (m, 3H), 7.01 (s, 1H), 2.45 (s, 3H); **¹³C NMR (CDCl₃)**: δ 137.8, 137.4, 136.4, 133.0, 130.4, 130.3, 129.7, 127.9, 123.9, 123.0, 122.1, 121.1, 120.9, 109.8, 94.3, 21.62; **HRMS [M+H]⁺**: calcd for C₁₆H₁₃N₂ 233.1073, found 233.1073.



8,10-Dimethylindolo[1,2-c]quinazoline (13e)



Pale yellow powder, **yield**: 73%, mp: 196-197 °C; **IR (KBr)**: 2926, 1460, 1383 (cm⁻¹); **¹H NMR (CDCl₃)**: δ 9.22 (s, 1H), 7.94 (dd, $J_1 = 7.7$ Hz, $J_2 = 1.1$ Hz, 1H), 7.68 (d, $J = 8.1$ Hz, 1H), 7.48-7.34 (m, 3H), 6.99 (s, 1H), 6.91 (s, 1H), 2.77 (s, 3H), 2.42 (s, 3H); **¹³C NMR (CDCl₃)**: δ 139.3, 138.8, 133.4, 133.2, 130.6, 128.9, 128.0, 127.7, 127.4, 127.0, 122.9, 122.2, 121.5, 118.3, 95.1, 21.4, 21.3; **HRMS [M+H]⁺**: calcd for C₁₇H₁₅N₂ 247.1232, found 247.1230.

References




- ¹ (a) Cacchi, S.; Fabrizi, G.; Pace, P. *J. Org. Chem.* **1998**, 63, 1001-1011; (b) Arcadi, A.; Cacchi, S.; Fabrizi, G.; Ghirga, F.; Goggiamani, A.; Iazzetti, A.; Marinelli, F. *Synthesis* **2018**, 50, 1133-1140.
- ² Arcadi, A.; Cacchi, S.; Fabrizi, G.; Ghirga, F.; Marinelli, F.; Parisi L. M. *Heterocycles*. **2004**, 64, 475.
- ³ Cacchi, S.; Fabrizi, G.; Pace, P. Marinelli, F. *Synlett* **1999**, 620.
- ⁴ Kumar, K. S; Ramulu, M. S.; Rajesham, B.; Kumar, N. P.; Voorab, V.; Kanchab, R. K. *Org. Biomol. Chem.*, **2017**,15, 4468.
- ⁵ Nitin T. Patil, Rahul D. Kavthe, Vivek S. Raut, Vaddu V. N. Reddy *J. Org. Chem.* **2009**, 6315.

NMR Spectra



10a





10b





10c




10d





10e





10e






10f






10g




10h




10i




10i




10j




10k




101




10m






10m




10n





10o




10p




13a




13b



13c



13d



13e

